Crispr Therapeutics’ stock soars as FDA-panel meeting raises hopes sickle-cell-disease drug will be approved

Crispr Therapeutics' stock rallied 12% Wednesday amid hopes a treatment for sickle-cell disease will win regulatory approval.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.